Nasal Levels of Antimicrobial Peptides in Allergic Asthma Patients and Healthy Controls: Differences and Effect of a Short 1,25(OH)2 Vitamin D3 Treatment

PLoS One. 2015 Nov 6;10(11):e0140986. doi: 10.1371/journal.pone.0140986. eCollection 2015.

Abstract

Background: Allergy is often accompanied by infections and lower levels of antimicrobial peptides (AMPs). Vitamin D has been shown to increase expression of selected AMPs. In this study we investigated whether antimicrobial peptide levels in nasal secretions of allergic asthma patients are lower than in healthy controls, and whether administration of the active form of vitamin D (1,25(OH)2D3) affects these antimicrobial peptide levels.

Methods: The levels of antimicrobial peptides in nasal secretions were compared between 19 allergic asthma patients and 23 healthy controls. The effect of seven days daily oral treatment with 2 μg 1,25(OH)2D3 on antimicrobial peptides in nasal secretions was assessed in a placebo-controlled cross-over clinical study.

Results: Levels of neutrophil α-defensins (human neutrophil peptides 1-3; HNP1-3) and lipocalin 2 (LCN2; also known as NGAL) were significantly lower in asthmatics, but no differences in LL-37 and SLPI were detected. Treatment with a short-term 1,25(OH)2D3 caused a small increase in HNP1-3, but not when the asthma and control groups were analyzed separately. LL-37, LCN2 and SLPI did not change after treatment with 1,25(OH)2D3.

Conclusion: Levels of the antimicrobial peptides HNP1-3 and LCN2 are lower in nasal secretions in asthmatics and are not substantially affected by a short-term treatment with active vitamin D.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • 25-Hydroxyvitamin D3 1-alpha-Hydroxylase / metabolism
  • Adolescent
  • Adult
  • Anti-Infective Agents / metabolism*
  • Antimicrobial Cationic Peptides / metabolism*
  • Asthma / drug therapy*
  • Asthma / metabolism
  • Bone Density Conservation Agents / therapeutic use*
  • Case-Control Studies
  • Cholecalciferol / therapeutic use*
  • Cross-Over Studies
  • Double-Blind Method
  • Early Intervention, Educational
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nasal Mucosa / metabolism*
  • Nitric Oxide / metabolism
  • Young Adult

Substances

  • Anti-Infective Agents
  • Antimicrobial Cationic Peptides
  • Bone Density Conservation Agents
  • Cholecalciferol
  • Nitric Oxide
  • 25-Hydroxyvitamin D3 1-alpha-Hydroxylase

Grants and funding

The authors received no specific funding for this work.